Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

P8828

Sigma-Aldrich

Pergolide mesylate salt

≥98%, solid

Synonym(s):

8β-[(Methylthio)methyl]-6-propylergoline methanesulfonate salt, Pergolide methanesulfonate salt

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C19H26N2S · CH4O3S
CAS Number:
Molecular Weight:
410.59
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

assay

≥98%

form

solid

optical activity

[α]20/D −35°, c = 0.2 in pyridine(lit.)

color

white

solubility

ethanol: 2 mg/mL
DMSO: 5.2 mg/mL
H2O: insoluble

originator

Valeant

storage temp.

−20°C

SMILES string

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(c34)[C@@]1([H])C[C@@H](CSC)CN2CCC

InChI

1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1

InChI key

UWCVGPLTGZWHGS-ZORIOUSZSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Dopaminergic agonist; suppresses pituitary secretion of prolactin; anti-Parkinsonian agent.

Features and Benefits

This compound was developed by Valeant. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 2 Oral

Storage Class

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nobuhiro Ooba et al.
Drug safety, 34(4), 329-338 (2011-03-23)
Use of the ergot-derived dopamine receptor agonists (cabergoline and pergolide) is associated with an increased risk of cardiac valvulopathy. Pergolide was withdrawn from the US market in 2007 because of the risk of valvular heart disease, while the European Medicines
Jos J Adam et al.
Neuroscience letters, 500(2), 113-117 (2011-06-28)
Using an anti-cue keypress task, we examined executive control in Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN) and dopaminergic medication. Across sessions, we varied stimulation (on, off) and dopaminergic medication (on, off).
Sachiko Nakaoka et al.
Internal medicine (Tokyo, Japan), 50(7), 687-694 (2011-04-07)
The ergot-derived dopamine agonists, cabergoline and pergolide, are associated with valvulopathy risk. In Japan, product labels were revised in April 2007 to recommend periodic echocardiography for patients taking these dopamine agonists, however, the compliance of physicians to follow through with
P Barone et al.
Neurology, 53(3), 573-579 (1999-08-17)
To determine whether pergolide monotherapy provides symptomatic relief in early PD. Early treatment with dopamine agonists may reduce the risk of motor fluctuations, which are most likely linked to levodopa therapy. Pergolide, a D1-D2 dopamine agonist, has been studied as
Alin Ciobica et al.
Journal of physiology and biochemistry, 68(1), 59-69 (2011-10-19)
One of the most widely used animal models of Parkinson's disease (PD) involves injecting 6-hydroxydopamine (6-OHDA) directly into the substantia nigra (SN). Some recent reports speculated that dopaminergic drugs may exert brain antioxidant activity, which could explain some of their

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service